912-352-7546

Med Spa, Telehealth, or Doctor’s Office: How to Choose Where to Get Weight-Loss Medication

By Dr. Don Gates, MD, Founder of Scale Solutions

Man exercising with resistance bands under live oaks in a Savannah park, for a guide comparing med spa vs doctor for weight-loss shots

The sign on the door matters less than the answers to about a dozen specific questions. A med spa, an online platform, and a medical office can all employ excellent, fully licensed clinicians — and any of the three can also hand you a syringe with little else attached to it. What separates a good experience from a risky one is who prescribes, whether the medication is FDA-approved or compounded, what gets evaluated before you start, how closely you’re followed afterward, who answers the phone when something goes wrong, and what happens once you reach your goal.

Obesity is treated as a chronic disease. These medications work while you take them, and the 2026 treatment standards are explicit that stopping usually brings the weight back. That makes this less a purchase than the start of an ongoing clinical relationship — the right lens to shop with.

Key Takeaways

  • The care setting is a weak proxy for quality. Evaluate the program, not the category.
  • Ask whether your medication is brand-name FDA-approved or compounded. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
  • Screening matters before the first dose: thyroid cancer history, pancreatitis, gastroparesis, pregnancy plans, and medications like insulin or sulfonylureas all change the picture.
  • The 2026 Standards of Care describe monthly follow-up for three months, then roughly quarterly through year one, then every three to six months long-term.
  • Ask what happens at goal weight before you start. A program with no maintenance plan is selling you half the treatment.

Med spa vs doctor: does it actually matter where you get a GLP-1?

It matters, but not the way most marketing suggests. Writing the prescription is the easy part. Reconciling your other medications, catching a contraindication in your family history, telling ordinary nausea from early pancreatitis, finding a dose you can tolerate, and planning for the years after the weight comes off — those are what distinguish programs.

Here is what each setting is typically structurally built around. Any clinic can exceed its category, so treat this as a starting point for questions, not a verdict.

SettingBuilt aroundCommon strengthsWhat to verify
Med spa / aesthetics practiceElective, on-site, procedure-based servicesIn-person contact, easy scheduling, local and familiarWho prescribes and who supervises; whether history and medications are reviewed; brand vs. compounded; what follow-up is included
Telehealth / online programAccess and scale across a wide geographySpeed, convenience, price transparency; useful when distance is a real barrierWhether you see the same clinician; brand vs. compounded and who compounds it; lab ordering; side-effect escalation; referrals
Medical practiceLongitudinal care of one patient over timeMedication reconciliation, exam, labs, referrals, portable records, maintenance planningActual experience with obesity pharmacotherapy; follow-up cadence; insurance handling; reachability between visits

The useful question isn’t “is a med spa okay?” It’s “does this program do what a chronic-disease medication requires?”

Who is prescribing, and does their training matter?

Yes, and you’re entitled to know exactly who it is. A prescription may be written by a physician (MD or DO), a nurse practitioner, or a physician assistant, with supervision and collaboration arrangements governed by state law. All are legitimate prescribers. What varies enormously is how much of that clinician’s practice is actually obesity medicine.

A clinician whose primary field is something else can prescribe these medications competently. But obesity carries cardiovascular, metabolic, musculoskeletal and psychological dimensions, and these drugs interact with common prescriptions. Specialty focus is reasonable to weigh — as you would for blood pressure or thyroid care. Ask who writes the prescription, whether you’ll see that same person at follow-up, and how much of their practice is weight management.

Is your medication brand-name FDA-approved, or compounded?

This is the most important question a patient can ask, and the one least often answered on a website.

An FDA-approved product — Wegovy, Zepbound, Saxenda, the Wegovy pill, Foundayo — has been reviewed by FDA for safety and effectiveness, is made under federal quality requirements, and carries the prescribing information FDA approved. A compounded medication is prepared by a state-licensed compounding pharmacy or an FDA-registered outsourcing facility. Compounding is legitimate and meets real needs, but FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. That isn’t an accusation about any pharmacy; it’s a structural difference you should be told about.

Context, verified as of August 19, 2026:

  • Semaglutide has not been on FDA’s shortage list since 2025, and tirzepatide since 2024. The shortage conditions that drove widespread compounding of copies have ended.
  • On March 3, 2026, FDA issued warning letters to 30 telehealth companies marketing compounded GLP-1 products. Violations cited included claims implying compounded products are equivalent to FDA-approved versions, and branding compounded drugs with the company’s own name or trademark without disclosure, which could falsely suggest the seller was the compounder. FDA Commissioner Marty Makary: “Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA’s approval process.”
  • As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide — likely undercounts, since state-licensed pharmacies aren’t required to report adverse events.
  • FDA’s June 15, 2026 advisory flags improper storage and shipping, dosing errors from units-versus-milligrams confusion, mislabeled products from unlicensed sources, and semaglutide salt forms with no established safety data. It also states retatrutide and cagrilintide cannot legally be used in compounding; neither is approved.
  • A May 1, 2026 FDA proposal (docket FDA-2018-N-3240) would exclude semaglutide, tirzepatide and liraglutide from the 503B bulk substances list, finding no clinical need — and noting that patient preference does not establish clinical need. Comments closed July 30, 2026. As of August 19, 2026 there is no final determination; it remains a proposal.

None of this means a patient using a compounded product did something wrong, or that any provider is acting improperly. It means you should get straight answers to three questions: Is this brand-name or compounded? If compounded, what facility prepares it? May I see the label?

Related: compounded versus brand-name semaglutide in Georgia.

What should happen before your first prescription?

A history and medication review — not just a height, a weight, and a credit card. The labeled contraindications for this class aren’t obscure, but they only get caught if someone asks about:

  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). GLP-1 receptor agonists for weight management carry a boxed warning for thyroid C-cell tumors based on rodent data and are contraindicated with this history.
  • Pancreatitis (inflammation of the pancreas) and gallbladder disease, both labeled concerns.
  • Gastroparesis — delayed stomach emptying. Oral semaglutide is not recommended in severe gastroparesis per its labeling.
  • Pregnancy or pregnancy plans. All approved obesity medications are contraindicated in pregnancy; the 2026 Standards of Care advise stopping at least two months before a planned pregnancy.
  • Insulin or sulfonylureas, which raise hypoglycemia risk in combination and often need adjustment.
  • Kidney function and dehydration risk, given acute kidney injury from volume depletion.
  • Upcoming surgery. Pulmonary aspiration during general anesthesia or deep sedation is a labeled warning; your anesthesia team needs to know.

Your full medication list belongs in that review, and this is the quietest risk in the category. GLP-1s slow gastric emptying, which can affect absorption of other oral medications, and they are often started by one clinician while someone else manages the blood pressure, thyroid, psychiatric or diabetes prescriptions you already take. Ask whether the program reconciles medications and will send a note to your primary care physician. If it doesn’t, the coordinating job falls to you.

Baseline lab testing is individualized — guidelines don’t prescribe one universal panel, because what’s appropriate depends on your history and other conditions. What shouldn’t vary is whether anyone reviews that history at all.

Related: lab work before starting a GLP-1.

What monitoring should you expect afterward?

More than most programs schedule. The 2026 Standards of Care treatment algorithm describes follow-up monthly for the first three months to monitor and modify treatment, then every three months for the first year, then every three to six months long-term. For phentermine, it describes monthly follow-up including blood pressure and pulse until the dose is stable.

The same standards address nutrition and muscle directly, which is where medication-only programs tend to fall short. They recommend monitoring nutritional intake with attention to preventing protein insufficiency and micronutrient deficiencies during active weight reduction; counseling on adequate protein and muscle-strengthening activity to limit the muscle loss that accompanies weight loss (the guideline text describes a minimum of 60 g of protein daily, often 1.2–1.6 g/kg per day during weight reduction); and considering referral to a registered dietitian nutritionist.

Ask whether follow-up visits are included in the quoted price. A low monthly medication cost with no follow-up attached is a different product than it appears.

Who manages side effects, and how fast can you reach them?

Find out before you need to know. Most GLP-1 side effects are gastrointestinal and manageable with dose adjustment, timing and hydration. Some are not routine.

One that’s genuinely under-discussed: the Wegovy prescribing information (rev. 06/2026) describes dysesthesia and related altered skin sensations — paresthesia, skin pain, sensitive skin, burning skin sensation — in trials of both the injection and the tablet, increasing with dose and blood levels. Reported rates were 22% at 7.2 mg, 6% at 2.4 mg and 0.3% on placebo. FDA notes it generally resolved on its own or with dose reduction. A patient who has never heard the word is understandably frightened by it, and a program that can’t be reached quickly turns a manageable problem into an ER visit.

Two areas where the internet often misleads. On January 13, 2026 (updated April 3, 2026) FDA requested removal of the suicidal behavior and ideation warning from Saxenda, Wegovy and Zepbound after reviewing 91 placebo-controlled trials covering 107,910 patients plus a cohort of 2.2 million users — but a label change is not a promise that no individual experiences a mood change, so report those either way. And as of August 19, 2026 there is no NAION warning in the US prescribing information for Ozempic, Wegovy, Mounjaro or Zepbound; the only eye-related labeling is diabetic retinopathy, a different condition. The UK’s MHRA issued a safety update in February 2026, so regulators currently differ. Report any new vision change promptly.

Ask: Who do I contact for side effects, how fast is the response, and is there after-hours coverage? Can you order labs or imaging, and can I be seen in person? And if I need a specialist — gastroenterology, a surgeon for the gallbladder, endocrinology if I’m not responding — do you have referral relationships here, and will my records follow me?

What happens when you reach your goal weight?

Ask before you start, because the answer defines the whole treatment. Recommendation 2.16 of the 2026 Standards of Care, graded A — the strongest evidence grade — states:

“Continue obesity medications after reaching treatment goals to maintain health benefits, as discontinuation often results in weight recurrence and worsening or reemergence of cardiometabolic risk factors or obesity-related diseases and complications”

The same recommendation adds a point that rarely reaches marketing: the individualized maintenance dose should balance efficacy, health benefits and tolerability, and “may not necessarily be the maximum approved dose.”

The trial data are consistent. In the STEP 1 extension, participants lost a mean 17.3% of body weight over 68 weeks on semaglutide; after withdrawal they regained 11.6 percentage points by week 120, ending at a net 5.6% below baseline — roughly two-thirds of the loss regained within about a year, with waist circumference, blood pressure, HbA1c, lipids and CRP largely reverting toward baseline. In SURMOUNT-4, after a 36-week lead-in producing 20.9% mean weight reduction, those randomized to continue tirzepatide lost a further 5.5% through week 88 while those switched to placebo regained 14.0%. All of these trials included lifestyle intervention throughout.

So ask: what does your program look like in year two? Is there a maintenance phase, a plan for dose adjustment, ongoing nutrition and strength guidance, and a clinician who still knows you?

Med Spa vs Doctor: Questions to Ask Any Weight-Loss Provider

Print this. Ask a med spa, ask an online platform, and ask a doctor’s office — including ours. A good program answers all twelve without hesitation.

  1. Who writes my prescription, what is their credential, and will I see the same clinician at follow-up?
  2. Is the medication a brand-name FDA-approved product or a compounded preparation?
  3. If compounded, which facility prepares it, and may I see the label?
  4. What screening happens before the first dose — thyroid cancer history, pancreatitis, gastroparesis, pregnancy plans, and my current medications?
  5. What lab work do you recommend for me, and who reviews the results?
  6. How often will I be seen, and are follow-up visits included in the price quoted?
  7. Who do I contact for side effects, how fast is the response, and is there after-hours coverage?
  8. Will you review my other prescriptions and communicate with my primary care physician?
  9. What is the plan when I reach my goal weight, and what does maintenance look like?
  10. What happens if I need an in-person exam, imaging, or a specialist referral?
  11. What is the total monthly cost, what does it include, and what changes if my dose changes?
  12. What would make you tell me this medication is not appropriate for me?

That last one is diagnostic. A program with no answer may not be screening for one.

A brief word on price: med spa vs doctor

Price is legitimate, and for many Coastal Georgia families it decides the question — Georgia has not expanded Medicaid, and Georgia Medicaid does not cover medications for weight loss. But compare like with like. Verified August 19, 2026: LillyDirect lists self-pay Zepbound at $299 for 2.5 mg and $399 for 5 mg, rising to $699 at the higher doses, with a refill offer that reduces those doses when a refill completes within 45 days. Foundayo (orforglipron) starts at $149 per month; Wegovy HD 7.2 mg is listed at $399. These programs carry expiration dates and change often — confirm current pricing directly.

A compounded product at a lower monthly price and a brand-name product at a higher one are a genuine trade-off. The mistake isn’t choosing one. It’s not knowing which one you chose.

When to Talk to Your Doctor

Routine follow-up is the right setting for ordinary nausea, constipation, reflux, fatigue, a plateau, dosing questions, mood changes, or plans to become pregnant. Don’t stop, start, or change a prescription on your own — that decision belongs with the clinician who knows your history.

Seek urgent or emergency care for:

  • Severe, persistent abdominal pain, particularly radiating to the back, with or without vomiting — a possible sign of pancreatitis
  • Severe upper-right abdominal pain, fever, or yellowing of the skin or eyes — possible gallbladder problems
  • Persistent vomiting or diarrhea with inability to keep fluids down, or dehydration signs such as dizziness, minimal urination or confusion, given the risk of acute kidney injury
  • Symptoms of severe low blood sugar — confusion, sweating, shakiness, loss of consciousness — especially if you take insulin or a sulfonylurea
  • Swelling of the face, lips or throat, or difficulty breathing
  • Sudden vision changes

Tell any surgeon or anesthesiologist that you take a GLP-1 before a procedure. Pulmonary aspiration during general anesthesia or deep sedation is a labeled warning for this class.

Scale Solutions & Coastal Georgia

Most of the new weight-loss options around Savannah, Pooler, Richmond Hill and the surrounding counties arrived either as aesthetics practices adding injections or as online platforms serving the whole country from somewhere else. Many are staffed by capable people. Our position isn’t that they shouldn’t exist — it’s that a condition treated for years deserves a clinician who knows your history, whom you see each visit, who can examine you when a symptom doesn’t add up, who knows which gastroenterologist or surgeon to call in Chatham or Bryan County, and who is still there in year three when the conversation shifts from losing weight to keeping it off.

Scale Solutions is a physician-led medical weight-management practice serving Savannah and Coastal Georgia. If you’re comparing options right now — or you already started somewhere and have questions you haven’t been able to get answered — you’re welcome to bring this list to us and ask every question on it. Reach out anytime.

Related: how our practice compares to online-only GLP-1 programs.

Related: how Dr. Gates monitors GLP-1 patients.

Related: what happens if you stop a GLP-1.

Related: protecting muscle during weight loss.

Related: check whether you meet GLP-1 eligibility criteria.

Related: what to expect at a first weight-loss appointment.

Frequently Asked Questions: Med Spa vs Doctor

Is it safe to get semaglutide from a med spa? It depends on the program, not the category. Many med spas employ licensed, capable clinicians. Ask who prescribes, whether the medication is brand-name or compounded, what screening happens before the first dose, how often you’ll be seen, and who you contact for side effects. If those answers are solid, the setting matters much less.

How do I know whether my medication is compounded? Ask directly and ask to see the label. FDA-approved products are labeled with their brand name — Wegovy, Zepbound, Saxenda, Foundayo. A compounded preparation is typically labeled by the compounding pharmacy or outsourcing facility. In March 2026 FDA cited some sellers for branding compounded drugs with their own company name in ways that obscured the actual compounder, so a logo on the vial is not the same as knowing who made it.

Is telehealth a bad way to get weight-loss medication? No. Telehealth solves real access problems, and for some patients it’s the difference between treatment and none. The questions are the same anywhere: brand or compounded, who prescribes, who follows up, who handles side effects, and what happens if you need an in-person exam or referral.

Do I need blood work before starting a GLP-1? Baseline testing is individualized, and guidelines don’t specify one panel for everyone. What isn’t optional is a real history review — thyroid cancer history, pancreatitis, gastroparesis, pregnancy plans, kidney and gallbladder history, and your full medication list.

What happens if I stop once I hit my goal? The 2026 Standards of Care recommend continuing obesity medications after reaching treatment goals, because discontinuation often brings weight recurrence and the return of cardiometabolic risk factors. In the STEP 1 extension, participants regained roughly two-thirds of lost weight within about a year of stopping. Maintenance dosing may not need to be the maximum approved dose — a conversation to have with your clinician.

Conclusion: Med Spa vs Doctor Comes Down to the Answers

Where you get weight-loss medication matters less than whether the program is built to treat a chronic condition over years rather than dispense a drug over months. Ask who prescribes, ask whether the product is FDA-approved or compounded, ask what’s screened before the first dose and monitored after it, ask who answers the phone when something goes wrong, and ask what happens at goal weight. Good providers in every setting welcome those questions.

If you’re weighing options in Savannah or Coastal Georgia — or you’re already on a GLP-1 and want a local physician to review your history, your medication list and your long-term plan — Scale Solutions is here. Bring the checklist. We’ll answer all twelve.

MEDICAL SOURCES & FURTHER READING

  1. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. June 15, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss — storage and shipping problems, dosing errors, salt forms, unlicensed sources; retatrutide and cagrilintide cannot legally be compounded.

  2. U.S. Food and Drug Administration. Warning letters issued to 30 telehealth companies marketing compounded GLP-1 products, March 3, 2026 (second action following September 2025), including the quoted statement from Commissioner Marty Makary. (fda.gov press announcement — exact URL to be confirmed at publication; see verification checklist.)

  3. U.S. Food and Drug Administration. Adverse event reports associated with compounded semaglutide (990) and compounded tirzepatide (more than 730), as of May 31, 2026. fda.gov (specific page URL to be confirmed at publication.)

  4. U.S. Food and Drug Administration / Federal Register. Proposal regarding bulk drug substances for use in compounding by 503B outsourcing facilities, docket FDA-2018-N-3240, published May 1, 2026; comment period closed July 30, 2026. No final determination as of August 19, 2026. federalregister.gov

  5. U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications. January 13, 2026; updated April 3, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp

  6. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, rev. 06/2026. accessdata.fda.gov — boxed warning for thyroid C-cell tumors; dysesthesia and altered skin sensation incidence; pancreatitis, gallbladder, acute kidney injury, hypoglycemia with insulin/sulfonylureas, and pulmonary aspiration warnings.

  7. Oral semaglutide safety-related labeling changes, October 17, 2025 and January 30, 2026 — acute kidney injury from volume depletion, severe GI adverse reactions, expanded pancreatitis counseling, and “not recommended in severe gastroparesis.” FDA Safety-related Labeling Changes database, accessdata.fda.gov (DrugNameID=2456).

  8. Gudzune KA, et al.; American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. January 13, 2026. DOI 10.2337/doci25-0008; also BMJ Open Diabetes Res Care 2026;13(Suppl 1), DOI 10.1136/bmjdrc-2025-005729. Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12815056/ — Rec 2.16 (duration of treatment, grade A), Recs 2.18–2.20 (nutrition, protein, muscle), follow-up cadence per treatment algorithm figures, pregnancy guidance.

  9. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. DOI 10.1111/dom.14725.

  10. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. DOI 10.1001/jama.2023.24945. PMID 38078870.

  11. Georgia Department of Community Health / CMS. Georgia State Plan Amendment GA-24-0001, effective January 1, 2024 (CMS-approved June 6, 2024) — excludes “agents used for anorexia, weight loss or weight gain” from covered outpatient drugs. https://www.medicaid.gov/medicaid/spa/downloads/GA-24-0001.pdf

  12. LillyDirect self-pay pricing (zepbound.lilly.com; Foundayo pricing) and NovoCare Pharmacy Wegovy HD pricing — prices verified August 19, 2026. Manufacturer pricing programs change frequently and carry expiration dates.

Scale Solutions editorial standards: https://scale-solutions.com/editorial-policy/